Evidence map›Paper›PMID 31182115›Full record

ReviewMolecular neurodegeneration2019

Neuronally derived extracellular vesicles: an emerging tool for understanding Alzheimer's disease.

Luke S Watson, Eric D Hamlett, Tyler D Stone, Catrina Sims-Robinson

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Molecular neurodegeneration, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

48 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Assess Alzheimer's Disease via Plasma Extracellular Vesicle-derived mRNA.medRxiv : the preprint server for health sciences · 2023
    Article
  16. MicroRNA expression in extracellular vesicles as a novel blood-based biomarker for Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2023
    Article
  17. Review
  18. Article
  19. Extracellular Vesicles as Therapeutic Resources in the Clinical Environment.International journal of molecular sciences · 2023
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Luke S WatsonDepartment of Neurology, Medical University of South Carolina, 96 Jonathan Lucas Street, 301 Clinical Sciences Building, MSC 606, Charleston, SC, 29425, USA.
Eric D HamlettDepartment of Pathology and Laboratory Medicine, Medical University of South Carolina, Charleston, SC, 29425, USA.
Tyler D StoneDepartment of Neurology, Medical University of South Carolina, 96 Jonathan Lucas Street, 301 Clinical Sciences Building, MSC 606, Charleston, SC, 29425, USA.
Catrina Sims-RobinsonDepartment of Neurology, Medical University of South Carolina, 96 Jonathan Lucas Street, 301 Clinical Sciences Building, MSC 606, Charleston, SC, 29425, USA. robinsoc@musc.edu.ORCID 0000-0003-4776-5839

Funding

Molecular Mechanisms Underlying Obesity-related Memory DeficitsR01NS099595 · NINDS · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI ROBINSON, CATRINA SIMS · 2018 to 2022
$1.8M
NINDS NIH HHS R01 NS099595
6 · The paper itself

Abstract

In order for Alzheimer's disease (AD) to manifest, cells must communicate "pathogenic material" such as proteins, signaling molecules, or genetic material to ensue disease propagation. Small extracellular vesicles are produced via the endocytic pathways and released by nearly all cell types, including neurons. Due to their intrinsic interrelationship with endocytic processes and autophagy, there has been increased interest in studying the role of these neuronally-derived extracellular vesicles (NDEVs) in the propagation of AD. Pathologic cargo associated with AD have been found in a number of studies, and NDEVs have been shown to induce pathogenesis in vivo and in vitro. Exogenous NDEVs are also shown to reduce plaque burden in AD models. Thus, the NDEV has the potential to become a useful biomarker, a pathologic potentiator, and a therapeutic opportunity. While the field of NDEV research in AD is still in its infancy, we review the current literature supporting these three claims.

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesBrainExtracellular VesiclesHumansNeuronstau ProteinsAmyloid beta-Peptidestau ProteinsAutophagyBeta-amyloidCognitive impairmentDementiaExosomeMammalian target of rapamycinNeurodegenerationTau

Identifiers

PMID31182115
PMCPMC6558712

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.